Share price movements
On May 28, Gilead Sciences (GILD) closed at $63.97, 4.37% lower than its previous day’s close, after Goldman Sachs analyst Terence Flynn reduced his target price on the company from $70 to $60 and changed his recommendation from a “neutral” to a “sell.”
The stock closed 6.05% higher than its 52-week low of $60.32 and 19.65% lower than its 52-week high of $79.61. The company’s market cap was $81.68 billion, and its PE, forward PE, PEG (PE-to-growth), PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 14.10x, 9.18x, 4.45x, 3.66x, 3.72x, and 2.93x, respectively.
On May 28, Biogen (BIIB) closed at $225.54, 0.67% lower than its previous day’s close, 4.36% higher than its 52-week low of $216.12, and 41.97% lower than its 52-week high of $388.67. The company has yet to recover from the blow of the discontinuation of its investigational therapy aducanumab in Alzheimer’s disease indications. On May 24, Biogen suffered another setback when its competitor Novartis (NVS) secured FDA approval for its pediatric spinal muscular atrophy therapy, Zolgensma.
On May 28, Biogen’s market cap was $44.12 billion, and its PE, forward PE, PEG, PS, PB, and PC ratios were 9.67x, 7.37x, 1.47x, 3.19x, 3.21x, and 11.29x, respectively.
Analysts’ recommendations and target prices
The consensus recommendation for Gilead Sciences is a “buy,” while the consensus recommendation for Biogen is a “hold.”
Wall Street analysts expect an upside of 24.76% for Gilead Sciences based on the company’s closing price on May 28. Analysts first reduced the company’s 12-month consensus target price from $80.54 in February to $80.43 in March. They raised it to $80.60 in April and reduced it to $79.81 in May.
Of the 29 analysts covering Gilead Sciences, seven have given it “strong buys,” 11 have given it “buys,” ten have given it “holds,” and one has given it a “sell.”
Wall Street analysts expect an upside of 12.51% for Biogen based on its closing price on May 28. Analysts reduced the stock’s 12-month consensus target price from $378.11 in February to $261.12 in March, $259.12 in April, and $253.75 in May.
Of the 33 analysts covering Biogen, one has given it a “strong buy,” five have given it “buys,” 25 have given it “holds,” and two have given it “sells.”